nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—CXCL8—urinary bladder cancer	0.277	0.483	CbGaD
Tolmetin—MPO—urinary bladder cancer	0.215	0.376	CbGaD
Tolmetin—MPO—Carboplatin—urinary bladder cancer	0.1	0.354	CbGbCtD
Tolmetin—MPO—Cisplatin—urinary bladder cancer	0.0858	0.302	CbGbCtD
Tolmetin—PTGS2—urinary bladder cancer	0.0807	0.141	CbGaD
Tolmetin—PTGS2—Cisplatin—urinary bladder cancer	0.0296	0.104	CbGbCtD
Tolmetin—PTGS2—Etoposide—urinary bladder cancer	0.0291	0.103	CbGbCtD
Tolmetin—PTGS1—Etoposide—urinary bladder cancer	0.0246	0.0866	CbGbCtD
Tolmetin—SLC22A6—Methotrexate—urinary bladder cancer	0.0142	0.0502	CbGbCtD
Tolmetin—CXCL8—prostate gland—urinary bladder cancer	0.00227	0.113	CbGeAlD
Tolmetin—TDO2—female reproductive system—urinary bladder cancer	0.00225	0.112	CbGeAlD
Tolmetin—CXCL8—smooth muscle tissue—urinary bladder cancer	0.00161	0.0801	CbGeAlD
Tolmetin—CXCL8—urethra—urinary bladder cancer	0.00152	0.0757	CbGeAlD
Tolmetin—TDO2—lymph node—urinary bladder cancer	0.00132	0.0656	CbGeAlD
Tolmetin—Suprofen—UGT2B7—urinary bladder cancer	0.00114	0.29	CrCbGaD
Tolmetin—CXCL8—vagina—urinary bladder cancer	0.00112	0.0558	CbGeAlD
Tolmetin—Cardiac failure congestive—Mitomycin—urinary bladder cancer	0.00101	0.0155	CcSEcCtD
Tolmetin—Urinary tract infection—Valrubicin—urinary bladder cancer	0.000996	0.0153	CcSEcCtD
Tolmetin—Haematuria—Valrubicin—urinary bladder cancer	0.000977	0.015	CcSEcCtD
Tolmetin—MPO—epithelium—urinary bladder cancer	0.000975	0.0486	CbGeAlD
Tolmetin—MPO—renal system—urinary bladder cancer	0.000905	0.0451	CbGeAlD
Tolmetin—Flatulence—Valrubicin—urinary bladder cancer	0.000789	0.0121	CcSEcCtD
Tolmetin—CXCL8—lymph node—urinary bladder cancer	0.000725	0.0361	CbGeAlD
Tolmetin—Indomethacin—UGT2B7—urinary bladder cancer	0.000723	0.184	CrCbGaD
Tolmetin—Drowsiness—Mitomycin—urinary bladder cancer	0.000706	0.0109	CcSEcCtD
Tolmetin—Renal failure—Mitomycin—urinary bladder cancer	0.000694	0.0107	CcSEcCtD
Tolmetin—Stomatitis—Mitomycin—urinary bladder cancer	0.000688	0.0106	CcSEcCtD
Tolmetin—Chest pain—Valrubicin—urinary bladder cancer	0.000682	0.0105	CcSEcCtD
Tolmetin—PTGS1—prostate gland—urinary bladder cancer	0.00063	0.0314	CbGeAlD
Tolmetin—Proteinuria—Gemcitabine—urinary bladder cancer	0.000608	0.00934	CcSEcCtD
Tolmetin—PTGS2—prostate gland—urinary bladder cancer	0.000602	0.03	CbGeAlD
Tolmetin—Protein urine present—Gemcitabine—urinary bladder cancer	0.000599	0.00921	CcSEcCtD
Tolmetin—Blood urea increased—Thiotepa—urinary bladder cancer	0.000599	0.00921	CcSEcCtD
Tolmetin—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.000535	0.00822	CcSEcCtD
Tolmetin—PTGS1—seminal vesicle—urinary bladder cancer	0.000533	0.0265	CbGeAlD
Tolmetin—Body temperature increased—Valrubicin—urinary bladder cancer	0.000517	0.00794	CcSEcCtD
Tolmetin—Abdominal pain—Valrubicin—urinary bladder cancer	0.000517	0.00794	CcSEcCtD
Tolmetin—PTGS2—seminal vesicle—urinary bladder cancer	0.000509	0.0254	CbGeAlD
Tolmetin—Blood urea increased—Gemcitabine—urinary bladder cancer	0.000504	0.00775	CcSEcCtD
Tolmetin—Body temperature increased—Carboplatin—urinary bladder cancer	0.000479	0.00736	CcSEcCtD
Tolmetin—Asthenia—Valrubicin—urinary bladder cancer	0.000469	0.00721	CcSEcCtD
Tolmetin—PTGS1—epithelium—urinary bladder cancer	0.000463	0.023	CbGeAlD
Tolmetin—Oedema—Mitomycin—urinary bladder cancer	0.00045	0.00692	CcSEcCtD
Tolmetin—Diarrhoea—Valrubicin—urinary bladder cancer	0.000447	0.00688	CcSEcCtD
Tolmetin—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000446	0.0222	CbGeAlD
Tolmetin—PTGS2—epithelium—urinary bladder cancer	0.000442	0.022	CbGeAlD
Tolmetin—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.000441	0.00678	CcSEcCtD
Tolmetin—Dizziness—Valrubicin—urinary bladder cancer	0.000432	0.00665	CcSEcCtD
Tolmetin—PTGS1—renal system—urinary bladder cancer	0.000429	0.0214	CbGeAlD
Tolmetin—Cardiac failure congestive—Gemcitabine—urinary bladder cancer	0.000427	0.00657	CcSEcCtD
Tolmetin—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000426	0.0212	CbGeAlD
Tolmetin—MPO—lymph node—urinary bladder cancer	0.000424	0.0211	CbGeAlD
Tolmetin—Vomiting—Valrubicin—urinary bladder cancer	0.000416	0.00639	CcSEcCtD
Tolmetin—PTGS2—renal system—urinary bladder cancer	0.00041	0.0204	CbGeAlD
Tolmetin—Headache—Valrubicin—urinary bladder cancer	0.00041	0.0063	CcSEcCtD
Tolmetin—Indomethacin—CXCL8—urinary bladder cancer	0.000409	0.104	CrCbGaD
Tolmetin—PTGS2—urethra—urinary bladder cancer	0.000403	0.0201	CbGeAlD
Tolmetin—Anaphylactoid reaction—Gemcitabine—urinary bladder cancer	0.000401	0.00616	CcSEcCtD
Tolmetin—Somnolence—Mitomycin—urinary bladder cancer	0.0004	0.00615	CcSEcCtD
Tolmetin—Haemolytic anaemia—Cisplatin—urinary bladder cancer	0.0004	0.00615	CcSEcCtD
Tolmetin—Cardiac failure congestive—Cisplatin—urinary bladder cancer	0.000398	0.00612	CcSEcCtD
Tolmetin—Nausea—Valrubicin—urinary bladder cancer	0.000388	0.00597	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Fluorouracil—urinary bladder cancer	0.000381	0.00586	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Cisplatin—urinary bladder cancer	0.000373	0.00574	CcSEcCtD
Tolmetin—Dysuria—Thiotepa—urinary bladder cancer	0.000372	0.00573	CcSEcCtD
Tolmetin—Cardiac failure congestive—Etoposide—urinary bladder cancer	0.000365	0.00561	CcSEcCtD
Tolmetin—Weight increased—Thiotepa—urinary bladder cancer	0.000362	0.00557	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Cisplatin—urinary bladder cancer	0.000361	0.00555	CcSEcCtD
Tolmetin—Body temperature increased—Mitomycin—urinary bladder cancer	0.000356	0.00547	CcSEcCtD
Tolmetin—Renal failure—Thiotepa—urinary bladder cancer	0.000349	0.00537	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Gemcitabine—urinary bladder cancer	0.000349	0.00537	CcSEcCtD
Tolmetin—Stomatitis—Thiotepa—urinary bladder cancer	0.000346	0.00532	CcSEcCtD
Tolmetin—PTGS1—female reproductive system—urinary bladder cancer	0.000344	0.0171	CbGeAlD
Tolmetin—Anaphylactoid reaction—Etoposide—urinary bladder cancer	0.000342	0.00526	CcSEcCtD
Tolmetin—Haematuria—Thiotepa—urinary bladder cancer	0.000339	0.00521	CcSEcCtD
Tolmetin—Epistaxis—Thiotepa—urinary bladder cancer	0.000335	0.00515	CcSEcCtD
Tolmetin—Agranulocytosis—Thiotepa—urinary bladder cancer	0.000331	0.00509	CcSEcCtD
Tolmetin—PTGS2—female reproductive system—urinary bladder cancer	0.000329	0.0164	CbGeAlD
Tolmetin—Asthenia—Mitomycin—urinary bladder cancer	0.000323	0.00497	CcSEcCtD
Tolmetin—Proteinuria—Methotrexate—urinary bladder cancer	0.000311	0.00478	CcSEcCtD
Tolmetin—PTGS1—vagina—urinary bladder cancer	0.000311	0.0155	CbGeAlD
Tolmetin—Diarrhoea—Mitomycin—urinary bladder cancer	0.000308	0.00474	CcSEcCtD
Tolmetin—Protein urine present—Methotrexate—urinary bladder cancer	0.000307	0.00471	CcSEcCtD
Tolmetin—Ketorolac—PTGS2—urinary bladder cancer	0.000303	0.0773	CrCbGaD
Tolmetin—Abdominal discomfort—Cisplatin—urinary bladder cancer	0.000299	0.0046	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.000298	0.00458	CcSEcCtD
Tolmetin—Dizziness—Mitomycin—urinary bladder cancer	0.000298	0.00458	CcSEcCtD
Tolmetin—Tinnitus—Thiotepa—urinary bladder cancer	0.000297	0.00457	CcSEcCtD
Tolmetin—PTGS2—vagina—urinary bladder cancer	0.000297	0.0148	CbGeAlD
Tolmetin—Glossitis—Methotrexate—urinary bladder cancer	0.000296	0.00456	CcSEcCtD
Tolmetin—Renal failure—Gemcitabine—urinary bladder cancer	0.000294	0.00451	CcSEcCtD
Tolmetin—Stomatitis—Gemcitabine—urinary bladder cancer	0.000291	0.00448	CcSEcCtD
Tolmetin—Bromfenac—PTGS2—urinary bladder cancer	0.000291	0.0741	CrCbGaD
Tolmetin—Vomiting—Mitomycin—urinary bladder cancer	0.000286	0.0044	CcSEcCtD
Tolmetin—Stomatitis—Fluorouracil—urinary bladder cancer	0.000286	0.0044	CcSEcCtD
Tolmetin—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.000285	0.00439	CcSEcCtD
Tolmetin—Haematuria—Gemcitabine—urinary bladder cancer	0.000285	0.00438	CcSEcCtD
Tolmetin—Indomethacin—PPARG—urinary bladder cancer	0.000282	0.0719	CrCbGaD
Tolmetin—Headache—Mitomycin—urinary bladder cancer	0.000282	0.00434	CcSEcCtD
Tolmetin—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.000279	0.00429	CcSEcCtD
Tolmetin—Glossitis—Epirubicin—urinary bladder cancer	0.000277	0.00426	CcSEcCtD
Tolmetin—Epistaxis—Fluorouracil—urinary bladder cancer	0.000277	0.00426	CcSEcCtD
Tolmetin—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.000274	0.00421	CcSEcCtD
Tolmetin—Renal failure—Cisplatin—urinary bladder cancer	0.000274	0.00421	CcSEcCtD
Tolmetin—Stomatitis—Cisplatin—urinary bladder cancer	0.000271	0.00417	CcSEcCtD
Tolmetin—Nausea—Mitomycin—urinary bladder cancer	0.000268	0.00411	CcSEcCtD
Tolmetin—Glossitis—Doxorubicin—urinary bladder cancer	0.000257	0.00395	CcSEcCtD
Tolmetin—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000254	0.0039	CcSEcCtD
Tolmetin—Renal failure—Etoposide—urinary bladder cancer	0.000251	0.00385	CcSEcCtD
Tolmetin—Stomatitis—Etoposide—urinary bladder cancer	0.000249	0.00382	CcSEcCtD
Tolmetin—Lumiracoxib—PTGS2—urinary bladder cancer	0.000247	0.063	CrCbGaD
Tolmetin—Blood urea increased—Epirubicin—urinary bladder cancer	0.000241	0.00371	CcSEcCtD
Tolmetin—Visual impairment—Cisplatin—urinary bladder cancer	0.000241	0.0037	CcSEcCtD
Tolmetin—Agranulocytosis—Etoposide—urinary bladder cancer	0.000238	0.00366	CcSEcCtD
Tolmetin—Tinnitus—Cisplatin—urinary bladder cancer	0.000233	0.00358	CcSEcCtD
Tolmetin—Lymphadenopathy—Methotrexate—urinary bladder cancer	0.000232	0.00357	CcSEcCtD
Tolmetin—Fenbufen—PTGS2—urinary bladder cancer	0.000225	0.0573	CrCbGaD
Tolmetin—Blood urea increased—Doxorubicin—urinary bladder cancer	0.000223	0.00343	CcSEcCtD
Tolmetin—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000222	0.00341	CcSEcCtD
Tolmetin—Lymphadenopathy—Epirubicin—urinary bladder cancer	0.000217	0.00334	CcSEcCtD
Tolmetin—Erythema multiforme—Etoposide—urinary bladder cancer	0.000217	0.00333	CcSEcCtD
Tolmetin—Flatulence—Cisplatin—urinary bladder cancer	0.000214	0.0033	CcSEcCtD
Tolmetin—Visual disturbance—Methotrexate—urinary bladder cancer	0.000209	0.00322	CcSEcCtD
Tolmetin—Vascular purpura—Epirubicin—urinary bladder cancer	0.000207	0.00319	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.000205	0.00315	CcSEcCtD
Tolmetin—Cardiac failure congestive—Epirubicin—urinary bladder cancer	0.000205	0.00315	CcSEcCtD
Tolmetin—Somnolence—Thiotepa—urinary bladder cancer	0.000201	0.0031	CcSEcCtD
Tolmetin—Lymphadenopathy—Doxorubicin—urinary bladder cancer	0.000201	0.00309	CcSEcCtD
Tolmetin—PTGS1—lymph node—urinary bladder cancer	0.000201	0.01	CbGeAlD
Tolmetin—Dyspepsia—Thiotepa—urinary bladder cancer	0.000199	0.00306	CcSEcCtD
Tolmetin—Chest pain—Gemcitabine—urinary bladder cancer	0.000199	0.00306	CcSEcCtD
Tolmetin—Chest pain—Fluorouracil—urinary bladder cancer	0.000195	0.003	CcSEcCtD
Tolmetin—Constipation—Thiotepa—urinary bladder cancer	0.000194	0.00298	CcSEcCtD
Tolmetin—Purpura—Epirubicin—urinary bladder cancer	0.000193	0.00296	CcSEcCtD
Tolmetin—PTGS2—lymph node—urinary bladder cancer	0.000192	0.00957	CbGeAlD
Tolmetin—Vascular purpura—Doxorubicin—urinary bladder cancer	0.000192	0.00295	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.000192	0.00295	CcSEcCtD
Tolmetin—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000191	0.00293	CcSEcCtD
Tolmetin—Oedema—Gemcitabine—urinary bladder cancer	0.000191	0.00293	CcSEcCtD
Tolmetin—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.000189	0.00291	CcSEcCtD
Tolmetin—Suprofen—PTGS2—urinary bladder cancer	0.000187	0.0477	CrCbGaD
Tolmetin—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000187	0.00288	CcSEcCtD
Tolmetin—Oedema—Fluorouracil—urinary bladder cancer	0.000187	0.00288	CcSEcCtD
Tolmetin—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000187	0.00287	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.000186	0.00285	CcSEcCtD
Tolmetin—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000185	0.00285	CcSEcCtD
Tolmetin—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000183	0.00282	CcSEcCtD
Tolmetin—Urticaria—Thiotepa—urinary bladder cancer	0.00018	0.00277	CcSEcCtD
Tolmetin—Body temperature increased—Thiotepa—urinary bladder cancer	0.000179	0.00275	CcSEcCtD
Tolmetin—Abdominal pain—Thiotepa—urinary bladder cancer	0.000179	0.00275	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000179	0.00274	CcSEcCtD
Tolmetin—Purpura—Doxorubicin—urinary bladder cancer	0.000178	0.00274	CcSEcCtD
Tolmetin—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000178	0.00273	CcSEcCtD
Tolmetin—Oedema—Cisplatin—urinary bladder cancer	0.000178	0.00273	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000177	0.00273	CcSEcCtD
Tolmetin—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000174	0.00267	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.000172	0.00264	CcSEcCtD
Tolmetin—Chest pain—Etoposide—urinary bladder cancer	0.00017	0.00261	CcSEcCtD
Tolmetin—Somnolence—Gemcitabine—urinary bladder cancer	0.000169	0.0026	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000167	0.00257	CcSEcCtD
Tolmetin—Somnolence—Fluorouracil—urinary bladder cancer	0.000167	0.00256	CcSEcCtD
Tolmetin—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000165	0.00253	CcSEcCtD
Tolmetin—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000164	0.00253	CcSEcCtD
Tolmetin—Gastritis—Epirubicin—urinary bladder cancer	0.000164	0.00252	CcSEcCtD
Tolmetin—Constipation—Gemcitabine—urinary bladder cancer	0.000163	0.0025	CcSEcCtD
Tolmetin—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000163	0.0025	CcSEcCtD
Tolmetin—Asthenia—Thiotepa—urinary bladder cancer	0.000162	0.0025	CcSEcCtD
Tolmetin—Dysuria—Methotrexate—urinary bladder cancer	0.00016	0.00246	CcSEcCtD
Tolmetin—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000159	0.00245	CcSEcCtD
Tolmetin—Diarrhoea—Thiotepa—urinary bladder cancer	0.000155	0.00238	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000155	0.00238	CcSEcCtD
Tolmetin—Drowsiness—Methotrexate—urinary bladder cancer	0.000153	0.00235	CcSEcCtD
Tolmetin—Gastritis—Doxorubicin—urinary bladder cancer	0.000152	0.00234	CcSEcCtD
Tolmetin—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000151	0.00232	CcSEcCtD
Tolmetin—Renal failure—Methotrexate—urinary bladder cancer	0.00015	0.00231	CcSEcCtD
Tolmetin—Dysuria—Epirubicin—urinary bladder cancer	0.00015	0.00231	CcSEcCtD
Tolmetin—Dizziness—Thiotepa—urinary bladder cancer	0.00015	0.0023	CcSEcCtD
Tolmetin—Stomatitis—Methotrexate—urinary bladder cancer	0.000149	0.00229	CcSEcCtD
Tolmetin—Urticaria—Fluorouracil—urinary bladder cancer	0.000149	0.00229	CcSEcCtD
Tolmetin—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000148	0.00228	CcSEcCtD
Tolmetin—Weight increased—Epirubicin—urinary bladder cancer	0.000146	0.00224	CcSEcCtD
Tolmetin—Haematuria—Methotrexate—urinary bladder cancer	0.000146	0.00224	CcSEcCtD
Tolmetin—Weight decreased—Epirubicin—urinary bladder cancer	0.000145	0.00223	CcSEcCtD
Tolmetin—Somnolence—Etoposide—urinary bladder cancer	0.000145	0.00222	CcSEcCtD
Tolmetin—Epistaxis—Methotrexate—urinary bladder cancer	0.000144	0.00222	CcSEcCtD
Tolmetin—Vomiting—Thiotepa—urinary bladder cancer	0.000144	0.00221	CcSEcCtD
Tolmetin—Drowsiness—Epirubicin—urinary bladder cancer	0.000143	0.0022	CcSEcCtD
Tolmetin—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000143	0.00219	CcSEcCtD
Tolmetin—Headache—Thiotepa—urinary bladder cancer	0.000142	0.00218	CcSEcCtD
Tolmetin—Renal failure—Epirubicin—urinary bladder cancer	0.000141	0.00216	CcSEcCtD
Tolmetin—Body temperature increased—Cisplatin—urinary bladder cancer	0.00014	0.00216	CcSEcCtD
Tolmetin—Stomatitis—Epirubicin—urinary bladder cancer	0.000139	0.00214	CcSEcCtD
Tolmetin—Constipation—Etoposide—urinary bladder cancer	0.000139	0.00214	CcSEcCtD
Tolmetin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000139	0.00214	CcSEcCtD
Tolmetin—Dysuria—Doxorubicin—urinary bladder cancer	0.000139	0.00213	CcSEcCtD
Tolmetin—Hepatitis—Methotrexate—urinary bladder cancer	0.000137	0.00211	CcSEcCtD
Tolmetin—Asthenia—Gemcitabine—urinary bladder cancer	0.000137	0.0021	CcSEcCtD
Tolmetin—Haematuria—Epirubicin—urinary bladder cancer	0.000136	0.0021	CcSEcCtD
Tolmetin—Weight increased—Doxorubicin—urinary bladder cancer	0.000135	0.00208	CcSEcCtD
Tolmetin—Epistaxis—Epirubicin—urinary bladder cancer	0.000135	0.00207	CcSEcCtD
Tolmetin—Nausea—Thiotepa—urinary bladder cancer	0.000135	0.00207	CcSEcCtD
Tolmetin—Weight decreased—Doxorubicin—urinary bladder cancer	0.000134	0.00206	CcSEcCtD
Tolmetin—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000133	0.00205	CcSEcCtD
Tolmetin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000133	0.00205	CcSEcCtD
Tolmetin—Drowsiness—Doxorubicin—urinary bladder cancer	0.000132	0.00203	CcSEcCtD
Tolmetin—Visual impairment—Methotrexate—urinary bladder cancer	0.000132	0.00203	CcSEcCtD
Tolmetin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00013	0.002	CcSEcCtD
Tolmetin—Renal failure—Doxorubicin—urinary bladder cancer	0.00013	0.002	CcSEcCtD
Tolmetin—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00013	0.00199	CcSEcCtD
Tolmetin—Urticaria—Etoposide—urinary bladder cancer	0.000129	0.00199	CcSEcCtD
Tolmetin—Stomatitis—Doxorubicin—urinary bladder cancer	0.000129	0.00198	CcSEcCtD
Tolmetin—Abdominal pain—Etoposide—urinary bladder cancer	0.000129	0.00198	CcSEcCtD
Tolmetin—Body temperature increased—Etoposide—urinary bladder cancer	0.000129	0.00198	CcSEcCtD
Tolmetin—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000129	0.00198	CcSEcCtD
Tolmetin—Hepatitis—Epirubicin—urinary bladder cancer	0.000128	0.00197	CcSEcCtD
Tolmetin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000128	0.00197	CcSEcCtD
Tolmetin—Tinnitus—Methotrexate—urinary bladder cancer	0.000128	0.00197	CcSEcCtD
Tolmetin—Asthenia—Cisplatin—urinary bladder cancer	0.000127	0.00196	CcSEcCtD
Tolmetin—Haematuria—Doxorubicin—urinary bladder cancer	0.000126	0.00194	CcSEcCtD
Tolmetin—Epistaxis—Doxorubicin—urinary bladder cancer	0.000125	0.00192	CcSEcCtD
Tolmetin—Dizziness—Fluorouracil—urinary bladder cancer	0.000124	0.0019	CcSEcCtD
Tolmetin—Visual impairment—Epirubicin—urinary bladder cancer	0.000124	0.0019	CcSEcCtD
Tolmetin—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000123	0.0019	CcSEcCtD
Tolmetin—Diarrhoea—Cisplatin—urinary bladder cancer	0.000122	0.00187	CcSEcCtD
Tolmetin—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000121	0.00187	CcSEcCtD
Tolmetin—Vomiting—Gemcitabine—urinary bladder cancer	0.000121	0.00186	CcSEcCtD
Tolmetin—Tinnitus—Epirubicin—urinary bladder cancer	0.00012	0.00184	CcSEcCtD
Tolmetin—Headache—Gemcitabine—urinary bladder cancer	0.000119	0.00183	CcSEcCtD
Tolmetin—Indomethacin—PTGS2—urinary bladder cancer	0.000119	0.0304	CrCbGaD
Tolmetin—Vomiting—Fluorouracil—urinary bladder cancer	0.000119	0.00183	CcSEcCtD
Tolmetin—Hepatitis—Doxorubicin—urinary bladder cancer	0.000119	0.00183	CcSEcCtD
Tolmetin—Headache—Fluorouracil—urinary bladder cancer	0.000117	0.0018	CcSEcCtD
Tolmetin—Asthenia—Etoposide—urinary bladder cancer	0.000117	0.00179	CcSEcCtD
Tolmetin—Visual impairment—Doxorubicin—urinary bladder cancer	0.000114	0.00176	CcSEcCtD
Tolmetin—Nausea—Gemcitabine—urinary bladder cancer	0.000113	0.00174	CcSEcCtD
Tolmetin—Vomiting—Cisplatin—urinary bladder cancer	0.000113	0.00174	CcSEcCtD
Tolmetin—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000112	0.00173	CcSEcCtD
Tolmetin—Diarrhoea—Etoposide—urinary bladder cancer	0.000111	0.00171	CcSEcCtD
Tolmetin—Nausea—Fluorouracil—urinary bladder cancer	0.000111	0.00171	CcSEcCtD
Tolmetin—Tinnitus—Doxorubicin—urinary bladder cancer	0.000111	0.0017	CcSEcCtD
Tolmetin—Flatulence—Epirubicin—urinary bladder cancer	0.00011	0.00169	CcSEcCtD
Tolmetin—Dizziness—Etoposide—urinary bladder cancer	0.000108	0.00165	CcSEcCtD
Tolmetin—Nausea—Cisplatin—urinary bladder cancer	0.000105	0.00162	CcSEcCtD
Tolmetin—Vomiting—Etoposide—urinary bladder cancer	0.000103	0.00159	CcSEcCtD
Tolmetin—Headache—Etoposide—urinary bladder cancer	0.000102	0.00157	CcSEcCtD
Tolmetin—Flatulence—Doxorubicin—urinary bladder cancer	0.000102	0.00157	CcSEcCtD
Tolmetin—Chest pain—Methotrexate—urinary bladder cancer	0.000102	0.00156	CcSEcCtD
Tolmetin—Anaphylactic shock—Methotrexate—urinary bladder cancer	9.74e-05	0.0015	CcSEcCtD
Tolmetin—Nausea—Etoposide—urinary bladder cancer	9.66e-05	0.00149	CcSEcCtD
Tolmetin—Thrombocytopenia—Methotrexate—urinary bladder cancer	9.54e-05	0.00147	CcSEcCtD
Tolmetin—Chest pain—Epirubicin—urinary bladder cancer	9.51e-05	0.00146	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—PTGS2—urinary bladder cancer	9.14e-05	0.00167	CbGpPWpGaD
Tolmetin—Oedema—Epirubicin—urinary bladder cancer	9.12e-05	0.0014	CcSEcCtD
Tolmetin—Anaphylactic shock—Epirubicin—urinary bladder cancer	9.12e-05	0.0014	CcSEcCtD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—urinary bladder cancer	9.04e-05	0.00165	CbGpPWpGaD
Tolmetin—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	9.02e-05	0.00165	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	8.93e-05	0.00163	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Epirubicin—urinary bladder cancer	8.93e-05	0.00137	CcSEcCtD
Tolmetin—CXCL8—Cellular Senescence—ATM—urinary bladder cancer	8.93e-05	0.00163	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—CDK4—urinary bladder cancer	8.89e-05	0.00162	CbGpPWpGaD
Tolmetin—Chest pain—Doxorubicin—urinary bladder cancer	8.8e-05	0.00135	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—CDKN1A—urinary bladder cancer	8.77e-05	0.0016	CbGpPWpGaD
Tolmetin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—CDKN1A—urinary bladder cancer	8.77e-05	0.0016	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—CCNE1—urinary bladder cancer	8.77e-05	0.0016	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—PTEN—urinary bladder cancer	8.75e-05	0.0016	CbGpPWpGaD
Tolmetin—Somnolence—Methotrexate—urinary bladder cancer	8.66e-05	0.00133	CcSEcCtD
Tolmetin—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	8.6e-05	0.00157	CbGpPWpGaD
Tolmetin—Dyspepsia—Methotrexate—urinary bladder cancer	8.58e-05	0.00132	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—SOD2—urinary bladder cancer	8.55e-05	0.00156	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—HPGDS—urinary bladder cancer	8.52e-05	0.00156	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—ENO2—urinary bladder cancer	8.52e-05	0.00156	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—TNF—urinary bladder cancer	8.51e-05	0.00155	CbGpPWpGaD
Tolmetin—CXCL8—LPA receptor mediated events—HRAS—urinary bladder cancer	8.49e-05	0.00155	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—IL2—urinary bladder cancer	8.47e-05	0.00155	CbGpPWpGaD
Tolmetin—Oedema—Doxorubicin—urinary bladder cancer	8.44e-05	0.0013	CcSEcCtD
Tolmetin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	8.44e-05	0.0013	CcSEcCtD
Tolmetin—TDO2—Metabolism—GSTT1—urinary bladder cancer	8.27e-05	0.00151	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—TP53—urinary bladder cancer	8.26e-05	0.00151	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—CCND1—urinary bladder cancer	8.26e-05	0.00151	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	8.26e-05	0.00127	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—GPX1—urinary bladder cancer	8.16e-05	0.00149	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—SRC—urinary bladder cancer	8.12e-05	0.00148	CbGpPWpGaD
Tolmetin—Somnolence—Epirubicin—urinary bladder cancer	8.11e-05	0.00125	CcSEcCtD
Tolmetin—Dyspepsia—Epirubicin—urinary bladder cancer	8.03e-05	0.00123	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—MMP9—urinary bladder cancer	8.02e-05	0.00146	CbGpPWpGaD
Tolmetin—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	8.01e-05	0.00146	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	7.98e-05	0.00146	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.97e-05	0.00122	CcSEcCtD
Tolmetin—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	7.94e-05	0.00145	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	7.82e-05	0.00143	CbGpPWpGaD
Tolmetin—Constipation—Epirubicin—urinary bladder cancer	7.8e-05	0.0012	CcSEcCtD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	7.77e-05	0.00142	CbGpPWpGaD
Tolmetin—Urticaria—Methotrexate—urinary bladder cancer	7.74e-05	0.00119	CcSEcCtD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	7.74e-05	0.00141	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—RB1—urinary bladder cancer	7.73e-05	0.00141	CbGpPWpGaD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	7.72e-05	0.00141	CbGpPWpGaD
Tolmetin—Abdominal pain—Methotrexate—urinary bladder cancer	7.7e-05	0.00118	CcSEcCtD
Tolmetin—Body temperature increased—Methotrexate—urinary bladder cancer	7.7e-05	0.00118	CcSEcCtD
Tolmetin—Somnolence—Doxorubicin—urinary bladder cancer	7.5e-05	0.00115	CcSEcCtD
Tolmetin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	7.46e-05	0.00115	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	7.44e-05	0.00136	CbGpPWpGaD
Tolmetin—Dyspepsia—Doxorubicin—urinary bladder cancer	7.43e-05	0.00114	CcSEcCtD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	7.38e-05	0.00135	CbGpPWpGaD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	7.28e-05	0.00133	CbGpPWpGaD
Tolmetin—Urticaria—Epirubicin—urinary bladder cancer	7.24e-05	0.00111	CcSEcCtD
Tolmetin—Constipation—Doxorubicin—urinary bladder cancer	7.22e-05	0.00111	CcSEcCtD
Tolmetin—Body temperature increased—Epirubicin—urinary bladder cancer	7.21e-05	0.00111	CcSEcCtD
Tolmetin—Abdominal pain—Epirubicin—urinary bladder cancer	7.21e-05	0.00111	CcSEcCtD
Tolmetin—PTGS1—Biological oxidations—GSTP1—urinary bladder cancer	7.2e-05	0.00132	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	7.08e-05	0.00129	CbGpPWpGaD
Tolmetin—Asthenia—Methotrexate—urinary bladder cancer	6.99e-05	0.00107	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—TNF—urinary bladder cancer	6.94e-05	0.00127	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.9e-05	0.00106	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	6.88e-05	0.00126	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—NQO1—urinary bladder cancer	6.87e-05	0.00125	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—CDKN2A—urinary bladder cancer	6.79e-05	0.00124	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—ATM—urinary bladder cancer	6.75e-05	0.00123	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—CDK4—urinary bladder cancer	6.72e-05	0.00123	CbGpPWpGaD
Tolmetin—Urticaria—Doxorubicin—urinary bladder cancer	6.7e-05	0.00103	CcSEcCtD
Tolmetin—Abdominal pain—Doxorubicin—urinary bladder cancer	6.67e-05	0.00103	CcSEcCtD
Tolmetin—Body temperature increased—Doxorubicin—urinary bladder cancer	6.67e-05	0.00103	CcSEcCtD
Tolmetin—Diarrhoea—Methotrexate—urinary bladder cancer	6.67e-05	0.00102	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—MYC—urinary bladder cancer	6.63e-05	0.00121	CbGpPWpGaD
Tolmetin—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	6.62e-05	0.00121	CbGpPWpGaD
Tolmetin—Asthenia—Epirubicin—urinary bladder cancer	6.54e-05	0.00101	CcSEcCtD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.51e-05	0.00119	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—EGFR—urinary bladder cancer	6.48e-05	0.00118	CbGpPWpGaD
Tolmetin—Dizziness—Methotrexate—urinary bladder cancer	6.44e-05	0.000991	CcSEcCtD
Tolmetin—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	6.42e-05	0.00117	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—IGFBP3—urinary bladder cancer	6.4e-05	0.00117	CbGpPWpGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	6.38e-05	0.00116	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	6.3e-05	0.00115	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	6.26e-05	0.00114	CbGpPWpGaD
Tolmetin—Diarrhoea—Epirubicin—urinary bladder cancer	6.24e-05	0.000959	CcSEcCtD
Tolmetin—Vomiting—Methotrexate—urinary bladder cancer	6.2e-05	0.000952	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—TNF—urinary bladder cancer	6.17e-05	0.00113	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	6.17e-05	0.00113	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	6.14e-05	0.00112	CbGpPWpGaD
Tolmetin—Headache—Methotrexate—urinary bladder cancer	6.1e-05	0.000938	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	6.08e-05	0.00111	CbGpPWpGaD
Tolmetin—Asthenia—Doxorubicin—urinary bladder cancer	6.05e-05	0.000931	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	6.03e-05	0.0011	CbGpPWpGaD
Tolmetin—Dizziness—Epirubicin—urinary bladder cancer	6.03e-05	0.000927	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—TP53—urinary bladder cancer	5.97e-05	0.00109	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—CREBBP—urinary bladder cancer	5.86e-05	0.00107	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—RB1—urinary bladder cancer	5.84e-05	0.00107	CbGpPWpGaD
Tolmetin—Vomiting—Epirubicin—urinary bladder cancer	5.8e-05	0.000891	CcSEcCtD
Tolmetin—Nausea—Methotrexate—urinary bladder cancer	5.79e-05	0.00089	CcSEcCtD
Tolmetin—Diarrhoea—Doxorubicin—urinary bladder cancer	5.77e-05	0.000888	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	5.75e-05	0.00105	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—GSTP1—urinary bladder cancer	5.73e-05	0.00105	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—HRAS—urinary bladder cancer	5.71e-05	0.00104	CbGpPWpGaD
Tolmetin—Headache—Epirubicin—urinary bladder cancer	5.71e-05	0.000878	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	5.7e-05	0.00104	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	5.62e-05	0.00103	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	5.6e-05	0.00102	CbGpPWpGaD
Tolmetin—Dizziness—Doxorubicin—urinary bladder cancer	5.58e-05	0.000858	CcSEcCtD
Tolmetin—CXCL8—Cellular Senescence—CDKN1A—urinary bladder cancer	5.55e-05	0.00101	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—TP53—urinary bladder cancer	5.44e-05	0.000993	CbGpPWpGaD
Tolmetin—Nausea—Epirubicin—urinary bladder cancer	5.42e-05	0.000833	CcSEcCtD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—TNF—urinary bladder cancer	5.41e-05	0.000988	CbGpPWpGaD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	5.37e-05	0.000981	CbGpPWpGaD
Tolmetin—Vomiting—Doxorubicin—urinary bladder cancer	5.36e-05	0.000825	CcSEcCtD
Tolmetin—TDO2—Metabolism—TYMS—urinary bladder cancer	5.33e-05	0.000973	CbGpPWpGaD
Tolmetin—Headache—Doxorubicin—urinary bladder cancer	5.29e-05	0.000813	CcSEcCtD
Tolmetin—TDO2—Metabolism—GSTM1—urinary bladder cancer	5.27e-05	0.000961	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—NCOR1—urinary bladder cancer	5.27e-05	0.000961	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—CDKN2A—urinary bladder cancer	5.13e-05	0.000937	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—GPX1—urinary bladder cancer	5.04e-05	0.000921	CbGpPWpGaD
Tolmetin—Nausea—Doxorubicin—urinary bladder cancer	5.01e-05	0.000771	CcSEcCtD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	4.98e-05	0.000909	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—ERCC2—urinary bladder cancer	4.95e-05	0.000904	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	4.94e-05	0.000901	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	4.89e-05	0.000893	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	4.87e-05	0.00089	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	4.84e-05	0.000884	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	4.75e-05	0.000867	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—MTHFR—urinary bladder cancer	4.65e-05	0.00085	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	4.59e-05	0.000839	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—HDAC4—urinary bladder cancer	4.58e-05	0.000837	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	4.42e-05	0.000808	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	4.41e-05	0.000806	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.39e-05	0.000802	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	4.37e-05	0.000798	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	4.33e-05	0.000791	CbGpPWpGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	4.31e-05	0.000786	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—CDKN1A—urinary bladder cancer	4.2e-05	0.000766	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GSTO2—urinary bladder cancer	4.18e-05	0.000764	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NAT1—urinary bladder cancer	4.18e-05	0.000764	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.12e-05	0.000751	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—EP300—urinary bladder cancer	3.99e-05	0.000729	CbGpPWpGaD
Tolmetin—PTGS2—Disease—GSTO2—urinary bladder cancer	3.97e-05	0.000724	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	3.88e-05	0.000709	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—GLI1—urinary bladder cancer	3.84e-05	0.000701	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	3.83e-05	0.000699	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	3.83e-05	0.000699	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	3.81e-05	0.000696	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	3.81e-05	0.000696	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	3.8e-05	0.000693	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—TP53—urinary bladder cancer	3.78e-05	0.00069	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—PPARG—urinary bladder cancer	3.77e-05	0.000689	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	3.71e-05	0.000678	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—CREBBP—urinary bladder cancer	3.63e-05	0.000662	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	3.62e-05	0.000661	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	3.52e-05	0.000643	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	3.51e-05	0.000641	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	3.5e-05	0.00064	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	3.45e-05	0.000629	CbGpPWpGaD
Tolmetin—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	3.42e-05	0.000624	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.33e-05	0.000607	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTO2—urinary bladder cancer	3.32e-05	0.000606	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NAT1—urinary bladder cancer	3.32e-05	0.000606	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.29e-05	0.0006	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.27e-05	0.000596	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	3.25e-05	0.000594	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PRSS3—urinary bladder cancer	3.17e-05	0.000579	CbGpPWpGaD
Tolmetin—PTGS2—Disease—SLC19A1—urinary bladder cancer	3.08e-05	0.000563	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	3.04e-05	0.000555	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PRSS3—urinary bladder cancer	3.01e-05	0.000549	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	2.99e-05	0.000546	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—PTGS2—urinary bladder cancer	2.97e-05	0.000542	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	2.9e-05	0.00053	CbGpPWpGaD
Tolmetin—PTGS2—Disease—HDAC4—urinary bladder cancer	2.87e-05	0.000523	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—TP53—urinary bladder cancer	2.86e-05	0.000522	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	2.84e-05	0.000518	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.79e-05	0.000509	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	2.74e-05	0.000499	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—IGF1—urinary bladder cancer	2.71e-05	0.000494	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	2.7e-05	0.000494	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—RBX1—urinary bladder cancer	2.63e-05	0.000481	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—PTEN—urinary bladder cancer	2.59e-05	0.000473	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	2.58e-05	0.000472	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.54e-05	0.000464	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—TYMP—urinary bladder cancer	2.53e-05	0.000463	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PRSS3—urinary bladder cancer	2.52e-05	0.00046	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TSC1—urinary bladder cancer	2.48e-05	0.000452	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—EP300—urinary bladder cancer	2.47e-05	0.000451	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.46e-05	0.000449	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.43e-05	0.000444	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	2.38e-05	0.000435	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.38e-05	0.000435	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.38e-05	0.000434	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—JAG1—urinary bladder cancer	2.36e-05	0.00043	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NAT2—urinary bladder cancer	2.29e-05	0.000418	CbGpPWpGaD
Tolmetin—PTGS2—Disease—LIG1—urinary bladder cancer	2.28e-05	0.000416	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.27e-05	0.000414	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.2e-05	0.000402	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.06e-05	0.000375	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.02e-05	0.000368	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—TYMP—urinary bladder cancer	2.01e-05	0.000367	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—RHOA—urinary bladder cancer	1.99e-05	0.000364	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—RRM2—urinary bladder cancer	1.98e-05	0.000361	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.97e-05	0.00036	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.93e-05	0.000353	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.93e-05	0.000353	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—S100B—urinary bladder cancer	1.91e-05	0.000348	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.84e-05	0.000336	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—ENO2—urinary bladder cancer	1.83e-05	0.000335	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—HPGDS—urinary bladder cancer	1.83e-05	0.000335	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.82e-05	0.000333	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.82e-05	0.000333	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NAT2—urinary bladder cancer	1.82e-05	0.000332	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—RHOA—urinary bladder cancer	1.81e-05	0.00033	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GSTT1—urinary bladder cancer	1.78e-05	0.000324	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.75e-05	0.00032	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ENO2—urinary bladder cancer	1.74e-05	0.000317	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—NCOR1—urinary bladder cancer	1.72e-05	0.000313	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—IL2—urinary bladder cancer	1.67e-05	0.000305	CbGpPWpGaD
Tolmetin—PTGS2—Disease—RBX1—urinary bladder cancer	1.65e-05	0.000301	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.62e-05	0.000296	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—RRM2—urinary bladder cancer	1.57e-05	0.000287	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—IL2—urinary bladder cancer	1.52e-05	0.000277	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TERT—urinary bladder cancer	1.51e-05	0.000276	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NQO1—urinary bladder cancer	1.48e-05	0.00027	CbGpPWpGaD
Tolmetin—PTGS2—Disease—JAG1—urinary bladder cancer	1.47e-05	0.000269	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.45e-05	0.000266	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.45e-05	0.000266	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.45e-05	0.000264	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.43e-05	0.000262	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1.41e-05	0.000258	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.39e-05	0.000254	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—FGFR3—urinary bladder cancer	1.39e-05	0.000253	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ESR1—urinary bladder cancer	1.35e-05	0.000246	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.25e-05	0.000228	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GSTP1—urinary bladder cancer	1.23e-05	0.000225	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.19e-05	0.000218	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CREBBP—urinary bladder cancer	1.18e-05	0.000216	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.17e-05	0.000214	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IGF1—urinary bladder cancer	1.17e-05	0.000213	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—EGFR—urinary bladder cancer	1.16e-05	0.000212	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.15e-05	0.000209	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.13e-05	0.000207	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.13e-05	0.000207	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—KRAS—urinary bladder cancer	1.1e-05	0.0002	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.08e-05	0.000198	CbGpPWpGaD
Tolmetin—PTGS2—Disease—NCOR1—urinary bladder cancer	1.07e-05	0.000196	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—RHOA—urinary bladder cancer	1.07e-05	0.000195	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.06e-05	0.000194	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ERCC2—urinary bladder cancer	1.01e-05	0.000184	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1e-05	0.000183	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.92e-06	0.000181	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—ERBB2—urinary bladder cancer	9.89e-06	0.000181	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTP1—urinary bladder cancer	9.78e-06	0.000179	CbGpPWpGaD
Tolmetin—PTGS2—Disease—MTHFR—urinary bladder cancer	9.49e-06	0.000173	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.46e-06	0.000173	CbGpPWpGaD
Tolmetin—PTGS2—Disease—TERT—urinary bladder cancer	9.46e-06	0.000173	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—HRAS—urinary bladder cancer	9.32e-06	0.00017	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—TYMS—urinary bladder cancer	9.09e-06	0.000166	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NCOR1—urinary bladder cancer	8.99e-06	0.000164	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GSTM1—urinary bladder cancer	8.99e-06	0.000164	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IL2—urinary bladder cancer	8.96e-06	0.000164	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CCND1—urinary bladder cancer	8.74e-06	0.00016	CbGpPWpGaD
Tolmetin—PTGS2—Disease—FGFR3—urinary bladder cancer	8.68e-06	0.000158	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—GPX1—urinary bladder cancer	8.61e-06	0.000157	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MMP9—urinary bladder cancer	8.48e-06	0.000155	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CDKN1A—urinary bladder cancer	8.45e-06	0.000154	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—ERCC2—urinary bladder cancer	8.45e-06	0.000154	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—PTEN—urinary bladder cancer	8.44e-06	0.000154	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PPARG—urinary bladder cancer	8.11e-06	0.000148	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—EP300—urinary bladder cancer	8.04e-06	0.000147	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—MTHFR—urinary bladder cancer	7.94e-06	0.000145	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—SRC—urinary bladder cancer	7.82e-06	0.000143	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CREBBP—urinary bladder cancer	7.79e-06	0.000142	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CREBBP—urinary bladder cancer	7.39e-06	0.000135	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—MYC—urinary bladder cancer	7.01e-06	0.000128	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—EGFR—urinary bladder cancer	6.86e-06	0.000125	CbGpPWpGaD
Tolmetin—PTGS2—Disease—RHOA—urinary bladder cancer	6.68e-06	0.000122	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KRAS—urinary bladder cancer	6.48e-06	0.000118	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PPARG—urinary bladder cancer	6.44e-06	0.000118	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PTGS2—urinary bladder cancer	6.38e-06	0.000117	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CREBBP—urinary bladder cancer	6.19e-06	0.000113	CbGpPWpGaD
Tolmetin—PTGS2—Disease—ERBB2—urinary bladder cancer	6.19e-06	0.000113	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TP53—urinary bladder cancer	5.76e-06	0.000105	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PTEN—urinary bladder cancer	5.57e-06	0.000102	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—HRAS—urinary bladder cancer	5.51e-06	0.000101	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—EP300—urinary bladder cancer	5.31e-06	9.69e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CDKN1A—urinary bladder cancer	5.29e-06	9.65e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—PTEN—urinary bladder cancer	5.28e-06	9.63e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—EP300—urinary bladder cancer	5.03e-06	9.19e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—SRC—urinary bladder cancer	4.89e-06	8.93e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PTEN—urinary bladder cancer	4.42e-06	8.07e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—MYC—urinary bladder cancer	4.39e-06	8e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—EGFR—urinary bladder cancer	4.29e-06	7.83e-05	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—EP300—urinary bladder cancer	4.21e-06	7.69e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—KRAS—urinary bladder cancer	4.05e-06	7.4e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—HRAS—urinary bladder cancer	3.44e-06	6.29e-05	CbGpPWpGaD
